Orlov Nicole Schaeffer Sells 30,000 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) insider Orlov Nicole Schaeffer sold 30,000 shares of Insmed stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the completion of the sale, the insider directly owned 36,461 shares in the company, valued at $7,073,434. This represents a 45.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Insmed Stock Performance

INSM opened at $193.22 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $197.45. The firm has a market capitalization of $41.21 billion, a PE ratio of -33.84 and a beta of 1.05. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The firm’s 50-day moving average price is $162.35 and its 200 day moving average price is $120.69.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter last year, the company earned ($1.27) earnings per share. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on INSM shares. Truist Financial upped their price objective on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a report on Thursday, August 14th. William Blair initiated coverage on Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Royal Bank Of Canada boosted their price objective on shares of Insmed from $139.00 to $215.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Cowen reaffirmed a “buy” rating on shares of Insmed in a research report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Wednesday, October 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.29.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after purchasing an additional 2,291,328 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after buying an additional 219,131 shares during the period. Capital International Investors increased its stake in Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after buying an additional 74,994 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after buying an additional 1,623,342 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after buying an additional 1,799,382 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.